JP2013531679A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531679A5
JP2013531679A5 JP2013518765A JP2013518765A JP2013531679A5 JP 2013531679 A5 JP2013531679 A5 JP 2013531679A5 JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013518765 A JP2013518765 A JP 2013518765A JP 2013531679 A5 JP2013531679 A5 JP 2013531679A5
Authority
JP
Japan
Prior art keywords
antibody
formulation
seq
amino acid
antibody fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518765A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531679A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042838 external-priority patent/WO2012003470A2/en
Publication of JP2013531679A publication Critical patent/JP2013531679A/ja
Publication of JP2013531679A5 publication Critical patent/JP2013531679A5/ja
Pending legal-status Critical Current

Links

JP2013518765A 2010-07-02 2011-07-01 抗体製剤 Pending JP2013531679A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36120910P 2010-07-02 2010-07-02
US61/361,209 2010-07-02
PCT/US2011/042838 WO2012003470A2 (en) 2010-07-02 2011-07-01 Antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015166305A Division JP2016026164A (ja) 2010-07-02 2015-08-26 抗体製剤

Publications (2)

Publication Number Publication Date
JP2013531679A JP2013531679A (ja) 2013-08-08
JP2013531679A5 true JP2013531679A5 (cg-RX-API-DMAC7.html) 2014-08-14

Family

ID=45402685

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013518765A Pending JP2013531679A (ja) 2010-07-02 2011-07-01 抗体製剤
JP2015166305A Pending JP2016026164A (ja) 2010-07-02 2015-08-26 抗体製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015166305A Pending JP2016026164A (ja) 2010-07-02 2015-08-26 抗体製剤

Country Status (9)

Country Link
US (1) US8754195B2 (cg-RX-API-DMAC7.html)
EP (1) EP2588141A4 (cg-RX-API-DMAC7.html)
JP (2) JP2013531679A (cg-RX-API-DMAC7.html)
CN (1) CN103108658B (cg-RX-API-DMAC7.html)
AU (2) AU2011274363A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012033457A2 (cg-RX-API-DMAC7.html)
CA (1) CA2803998A1 (cg-RX-API-DMAC7.html)
SG (1) SG186421A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012003470A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
TW201241008A (en) * 2010-10-01 2012-10-16 Alexion Pharma Inc Polypeptides that bind to human complement component C5
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
SG11201407779YA (en) * 2012-06-21 2015-02-27 Ucb Pharma Sa Pharmaceutical formulation
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP4285928A3 (en) * 2013-09-27 2024-03-13 F. Hoffmann-La Roche AG Anti-pdl1 antibody formulations
JP6799904B2 (ja) * 2014-07-31 2020-12-16 キユーピー株式会社 含水エタノール製剤及びその製造方法、並びに、リゾチーム加工品及び/又はその塩並びにその製造方法
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2016077451A1 (en) 2014-11-12 2016-05-19 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
DK3380525T3 (da) 2015-11-25 2024-01-29 Immunogen Inc Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
EP3383435A4 (en) 2015-11-30 2019-07-10 Medimmune, LLC OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
CN114404371A (zh) 2015-12-16 2022-04-29 瑞泽恩制药公司 制造蛋白质微粒的组合物和方法
CN105920600A (zh) * 2016-04-19 2016-09-07 上海景泽生物技术有限公司 一种稳定的抗vegf抗体制剂及其用途
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
JP2024502825A (ja) 2020-12-30 2024-01-23 エーマックス バイオ, インコーポレイテッド 抗体の局所的延長放出

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
WO1990010013A1 (en) 1989-02-09 1990-09-07 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce TYPE oc PLATELET-DERIVED GROWTH FACTOR RECEPTOR GENE
ES2147729T3 (es) 1991-01-31 2000-10-01 Cor Therapeutics Inc Dominios de la region extracelular de polipeptidos receptores de factor de crecimiento derivado de plaquetas humano.
IE920318A1 (en) 1991-01-31 1992-07-29 Univ California Human platelet-derived growth factor receptors
US5444151A (en) 1992-05-15 1995-08-22 Ludwig Institute For Cancer Research Platelet derived growth factor antagonists
DK1516628T3 (da) * 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
EP0999853B1 (en) * 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
ATE442862T2 (de) * 2000-10-12 2009-10-15 Genentech Inc Niederviskose konzentrierte proteinformulierungen
DE60235013D1 (de) 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
EP1475101B1 (en) * 2002-02-14 2010-10-27 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
WO2004050850A2 (en) 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to phospholipase a2 and uses thereof
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CA2560046A1 (en) 2004-03-16 2005-09-22 Dnavec Research Inc. Methods for suppressing tumor proliferation
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
RU2502523C2 (ru) * 2005-06-17 2013-12-27 Имклоун Элэлси АНТИТЕЛА ПРОТИВ PDGFRα ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОЙ ОПУХОЛИ КОСТИ
MX2008015852A (es) * 2006-06-14 2009-02-23 Imclone Systems Inc Formulaciones liofilizadas de anticuerpos anti-egfr.
CL2007002225A1 (es) * 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
JP5631591B2 (ja) * 2006-10-06 2014-11-26 アムジエン・インコーポレーテツド 安定な抗体製剤
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery

Similar Documents

Publication Publication Date Title
JP2013531679A5 (cg-RX-API-DMAC7.html)
Shang et al. Respiratory syncytial virus: from pathogenesis to potential therapeutic strategies
Mejias et al. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection
JP2013543505A5 (cg-RX-API-DMAC7.html)
JP2024016177A5 (cg-RX-API-DMAC7.html)
JP2013500947A5 (cg-RX-API-DMAC7.html)
CN111971062A (zh) 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
RU2012131099A (ru) Препарат антитела
JP2021504372A5 (cg-RX-API-DMAC7.html)
JP2018188437A5 (cg-RX-API-DMAC7.html)
JP2019504086A5 (cg-RX-API-DMAC7.html)
JP2018076350A5 (cg-RX-API-DMAC7.html)
JP2016534052A5 (cg-RX-API-DMAC7.html)
RU2017107847A (ru) Стабильный состав на основе антитела к il-4r-альфа
Hassett et al. Development of a highly thermostable, adjuvanted human papillomavirus vaccine
WO2010100200A3 (en) Lyophilised antibody formulation
RU2011127913A (ru) Составы, содержащие антитела
CN111050791A (zh) 用于抗tim-3抗体的给药方案及其用途
JP2020509031A5 (cg-RX-API-DMAC7.html)
JP2020158505A5 (cg-RX-API-DMAC7.html)
JP2019509311A5 (cg-RX-API-DMAC7.html)
JP2016520075A5 (cg-RX-API-DMAC7.html)
JP2017514868A5 (cg-RX-API-DMAC7.html)
JP7467438B2 (ja) 抗rsv抗体の製剤及びその使用方法
JP2013537212A5 (cg-RX-API-DMAC7.html)